Cost-effectiveness of Ximelagatran for Stroke Prevention—Reply
Publication
, Journal Article
Published in: JAMA
June 15, 2005
Duke Scholars
Published In
JAMA
DOI
ISSN
0098-7484
Publication Date
June 15, 2005
Volume
293
Issue
23
Start / End Page
2860 / 2860
Publisher
American Medical Association (AMA)
Related Subject Headings
- General & Internal Medicine
- 42 Health sciences
- 32 Biomedical and clinical sciences
- 11 Medical and Health Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Cost-effectiveness of Ximelagatran for Stroke Prevention—Reply. (2005). JAMA, 293(23), 2860–2860. https://doi.org/10.1001/jama.293.23.2861-a
“Cost-effectiveness of Ximelagatran for Stroke Prevention—Reply.” JAMA 293, no. 23 (June 15, 2005): 2860–2860. https://doi.org/10.1001/jama.293.23.2861-a.
Cost-effectiveness of Ximelagatran for Stroke Prevention—Reply. JAMA. 2005 Jun 15;293(23):2860–2860.
“Cost-effectiveness of Ximelagatran for Stroke Prevention—Reply.” JAMA, vol. 293, no. 23, American Medical Association (AMA), June 2005, pp. 2860–2860. Crossref, doi:10.1001/jama.293.23.2861-a.
Cost-effectiveness of Ximelagatran for Stroke Prevention—Reply. JAMA. American Medical Association (AMA); 2005 Jun 15;293(23):2860–2860.
Published In
JAMA
DOI
ISSN
0098-7484
Publication Date
June 15, 2005
Volume
293
Issue
23
Start / End Page
2860 / 2860
Publisher
American Medical Association (AMA)
Related Subject Headings
- General & Internal Medicine
- 42 Health sciences
- 32 Biomedical and clinical sciences
- 11 Medical and Health Sciences